Molecular Cancer Therapeutics · 2019 · 44 citations · 34 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular Cell BiologyMolecular OncologyCancer Cell SignalingCell Cycle ControlCell Cycle SignalingCell-cycle RegulationSignal Transduction In CancerTherapeutic ResistanceAcquired Resistance MechanismsCdk InhibitorsCell Cycle InhibitionCell Cycle InhibitorsNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentProtein Kinase InhibitorsResistance To Cell Cycle-targeted Drugs
Abstract CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor–positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non–small cell lung cancer (NSCLC). However, their clinical utility is often limited by drug resistance. Here, we sought to better understand the resistant mechanisms and help devise potential strategies to overcome this challenge. We show that treatment with CDK4/6 inhibitors in both ER+ breast cancer and KRAS-mutant NSCLC cells induces feedback upregulation of cyclin D1, CDK4, and cyclin E1, mediating drug resistance. We demonstrate that rocaglates, which preferentially target translation of key cell-cycle regulators, effectively suppress this feedback upregulation induced by CDK4/6 inhibition. Consequently, combination treatment of CDK4/6 inhibitor palbociclib with the eukaryotic initiation factor (eIF) 4A inhibitor, CR-1-31-B, is synergistic in suppressing the growth of these cancer cells in vitro and in vivo. Furthermore, ER+ breast cancer and KRAS-mutant NSCLC cells that acquired resistance to palbociclib after chronic drug exposure are also highly sensitive to this combination treatment strategy. Our findings reveal a novel strategy using eIF4A inhibitors to suppress cell-cycle feedback response and to overcome resistance to CDK4/6 inhibition in cancer.
34
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
Nicholas C. Turner, Dennis J. Slamon, Jungsil Ro et al. · New England Journal of Medicine · 2018 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17